The Senate Aging Committee, which is holding the hearing April 27, sent Mr. Pearson a subpoena to testify. The hearing will “examine how Valeant Pharmaceuticals dramatically increased the price of certain lifesaving drugs that it acquired,” according to The Wall Street Journal.
Laval, Quebec, Canada-based Valeant has taken the brunt of the criticism waged against the pharmaceutical industry for high drug prices since the Wall Street Journal last year reported the company was purchasing the rights to certain medications and then substantially raising their prices. Valeant said it adjusted certain underpriced drugs to reflect market value. However, the company recently said it wouldn’t continue this practice.
Last week, Valeant’s board of directors launched a search to replace Mr. Pearson. He will remain onboard until a replacement is found.
More articles on finance:
Bloomberg, other philanthropists give Johns Hopkins $125M for new cancer institute
Healthcare coverage changes for the poor in Mass.: 8 things to know
Health officials emphasize drug treatment, mental health to get states to expand Medicaid
